| Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseases |
36 |
| Metabolic adaptation of cancer and immune cells mediated by hypoxia-inducible factors |
33 |
| Control of metabolism by p53-Cancer and beyond |
33 |
| Metabolic reprogramming for cancer cells and their microenvironment: Beyond the Warburg Effect |
32 |
| Many ways to resistance: How melanoma cells evade targeted therapies |
32 |
| The emerging role of circRNAs and their clinical significance in-human cancers |
31 |
| Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer |
29 |
| Extracellular vesicles and anti-cancer drug resistance |
26 |
| Nanoparticle-mediated targeted drug delivery for breast cancer treatment |
26 |
| Mechanisms of acquired tumor drug resistance |
25 |
| Hybrid epithelial/mesenchymal phenotype(s): The 'fittest' for metastasis? |
24 |
| Applications of metabolomics to study cancer metabolism |
22 |
| Exosomes in cancer development, metastasis, and immunity |
21 |
| EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer |
21 |
| The key role of extracellular vesicles in the metastatic process |
21 |
| What is the blood concentration of extracellular vesicles? Implications for the use of extracellular vesicles as blood-borne biomarkers of cancer |
21 |
| Dynamic matrisome: ECM remodeling factors licensing cancer progression and metastasis |
20 |
| Gluconeogenesis in cancer cells - Repurposing of a starvation-induced metabolic pathway? |
20 |
| Genetic and metabolic hallmarks of clear cell renal cell carcinoma |
18 |
| High Mobility Group A (HMGA) proteins: Molecular instigators of breast cancer onset and progression |
18 |
| Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine |
17 |
| Colorectal cancer prevention: Immune modulation taking the stage |
17 |
| The role of necroptosis in cancer: A double-edged sword? |
17 |
| Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents |
17 |
| Piwi-interacting RNAs (piRNAs) and cancer: Emerging biological concepts and potential clinical implications |
17 |
| MicroRNAs as potential liquid biopsy biomarkers in colorectal cancer: A systematic review |
16 |
| The pro-tumorigenic effects of metabolic alterations in glioblastoma including brain tumor initiating cells |
16 |
| Phosphate toxicity and tumorigenesis |
16 |
| Pyruvate kinase M2: A multifarious enzyme in non-canonical localization to promote cancer progression |
16 |
| Combination therapies with HSP90 inhibitors against colorectal cancer |
15 |
| Targeting acidity in cancer and diabetes |
15 |
| The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance |
15 |
| ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies |
15 |
| Cell death in photodynamic therapy: From oxidative stress to anti-tumor immunity |
15 |
| Unraveling the journey of cancer stem cells from origin to metastasis |
14 |
| Functional analysis of Cullin 3 E3 ligases in tumorigenesis |
14 |
| The AP-1 transcriptional complex: Local switch or remote command? |
14 |
| The power of small changes: Comprehensive analyses of microbial dysbiosis in breast cancer |
14 |
| Microcalcifications in breast cancer: From pathophysiology to diagnosis and prognosis |
13 |
| Glutaminase isoenzymes in the metabolic therapy of cancer |
13 |
| The emerging role for Cullin 4 family of E3 ligases in tumorigenesis |
13 |
| EMT, stemness and tumor plasticity in aggressive-variant neuroendocrine prostate cancers |
12 |
| MEF2 and the tumorigenic process, hic sunt leones |
12 |
| Functional analysis of deubiquitylating enzymes in tumorigenesis and development |
12 |
| Role of tumor-derived exosomes in cancer metastasis |
10 |
| Long pentraxin 3: A novel multifaceted player in cancer |
10 |
| Genetic host factors in Helicobacter pylori-induced carcinogenesis: Emerging new paradigms |
10 |
| Clinical validity of saliva and novel technology for cancer detection |
10 |
| Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment |
10 |
| Targeting the mTOR regulatory network in hepatocellular carcinoma: Are we making headway? |
10 |
